Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of MBX 2109 in Healthy Participants
NCT05158335Phase 1Completed
- Sponsor
- MBX Biosciences, Inc.
- Start
- Nov 2021
- Primary completion
- Jun 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of canvuparatide in hypoparathyroidism (3 arms), sponsored by MBX Biosciences, Inc. Primary endpoint: Safety and Tolerability (Incidence of Adverse Events) at Day 60. Started Nov 2021; status: completed.
02
Drugs
canvuparatide
03
Conditions
hypoparathyroidism
Beyond the preview
Go deeper on NCT05158335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05158335.